Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme

Joshua Mansour, Braxton Fields, Samuel Macomson, Olivier Rixe

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1–0.4 % of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.

Original languageEnglish (US)
Pages (from-to)395-398
Number of pages4
JournalTargeted Oncology
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Pineal Gland
Glioblastoma
temozolomide
Neoplasms
Therapeutics
Radiation
Adjuvant Chemotherapy
Standard of Care
Brain Neoplasms
Glioma
Bevacizumab
Research

Keywords

  • Bevacizumab
  • Glioblastoma multiforme
  • Pineal gland

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. / Mansour, Joshua; Fields, Braxton; Macomson, Samuel; Rixe, Olivier.

In: Targeted Oncology, Vol. 9, No. 4, 01.01.2014, p. 395-398.

Research output: Contribution to journalArticle

Mansour, Joshua ; Fields, Braxton ; Macomson, Samuel ; Rixe, Olivier. / Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. In: Targeted Oncology. 2014 ; Vol. 9, No. 4. pp. 395-398.
@article{8f429562f77d43409061b36ad9550035,
title = "Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1–0.4 {\%} of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.",
keywords = "Bevacizumab, Glioblastoma multiforme, Pineal gland",
author = "Joshua Mansour and Braxton Fields and Samuel Macomson and Olivier Rixe",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11523-014-0327-8",
language = "English (US)",
volume = "9",
pages = "395--398",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme

AU - Mansour, Joshua

AU - Fields, Braxton

AU - Macomson, Samuel

AU - Rixe, Olivier

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1–0.4 % of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.

AB - Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas. Current standard treatment for GBM involves a combination of cytoreduction through surgical resection, followed by radiation with concomitant and adjuvant chemotherapy (temozolomide). The role of bevacizumab in the treatment of GBM continues to be a topic of ongoing research and debate. Despite aggressive treatment, these tumors remain undoubtedly fatal, especially in the elderly. Furthermore, tumors present in the pineal gland are extremely rare, accounting for only 0.1–0.4 % of all adult brain tumors, with this location adding to the complexity of treatment. We present a case of GBM, at the rare location of pineal gland, in an elderly patient who was refractory to initial standard of care treatment with radiation and concomitant and adjuvant temozolomide, but who developed a significant response to anti-angiogenic therapy using bevacizumab.

KW - Bevacizumab

KW - Glioblastoma multiforme

KW - Pineal gland

UR - http://www.scopus.com/inward/record.url?scp=84940291292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940291292&partnerID=8YFLogxK

U2 - 10.1007/s11523-014-0327-8

DO - 10.1007/s11523-014-0327-8

M3 - Article

C2 - 24998223

AN - SCOPUS:84940291292

VL - 9

SP - 395

EP - 398

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -